ProQuest Associates IV’s Zosano Pharma Corporation ZSAN Stock Holding History

ProQuest Associates IV’s Portfolio ZSAN Stock Details ZSAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-328	Closed	-$910K	–	6
2015 Q3	$910K	Hold	328	–	–	0.22%	5
2015 Q2	$1.67M	Hold	328	–	–	0.34%	5
2015 Q1	$2.32M	Buy	+328	New	+$2.46M	0.76%	5

Other funds holding ZSAN

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

ProQuest Associates IV's ZSAN Position: Q4 2015 in Review

ProQuest Associates IV sold out of Zosano Pharma Corporation (ZSAN) in Q4 2015, closing a stake of 328 shares — an estimated $910K sold.

ProQuest Associates IV first reported a position in ZSAN in Q1 2015 and held it in 3 quarters. The position peaked at $2.32M in Q1 2015. 13 funds tracked by Wall St. Rank hold ZSAN as of Q4 2015.

ProQuest Associates IV reported no remaining Zosano Pharma Corporation position as of Q4 2015 after selling out during the quarter.
ProQuest Associates IV sold 328 Zosano Pharma Corporation shares in Q4 2015, an estimated $910K.
ProQuest Associates IV first reported a position in Zosano Pharma Corporation in Q1 2015 and held it in 3 quarters.
ProQuest Associates IV's Zosano Pharma Corporation position peaked at $2.32M in Q1 2015.
13 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q4 2015.

Based on ProQuest Associates IV's 13F filing for Q4 2015, filed 12 Feb 2016.